Uterine fibroids: synthesis of modern knowledge

Literature review

Authors

  • K.D. Plaksiieva SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-3021-4515
  • T.F. Tatarchuk SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine https://orcid.org/0000-0002-5498-4143
  • N.V. Kosei SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv, Ukraine https://orcid.org/0000-0003-3085-3285
  • K.Y. Melnyk SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv , Ukraine https://orcid.org/0000-0001-9847-2396
  • O.S. Kozlov О.О. Bogomolets National Medical University, Kyiv , Ukraine https://orcid.org/0000-0003-1034-0909

DOI:

https://doi.org/10.18370/2309-4117.2022.63.8-18

Keywords:

uterine fibroids, fertility, myomectomy, uterine artery embolization

Abstract

Uterine fibroids is an extremely common tumor of the female reproductive system in the population. The problem of this pathology is the diversity of symptoms, mediated by the variety of sizes and locations of myomas, significant impact on reproductive function and frequent misunderstanding of the tumor nature, which leads to unwarranted hysterectomies, even among young women.
Authors review the literature on the basis of modern guidelines, which reveals the potential of preserving methods of treatment of fibroids. It is also attempted to answer the most common questions about this pathology.
The incidence of uterine fibroids increases with age. Fibroids are hormone dependent tumors, but the obvious cause has not yet been identified, although various risk factors are known, both modified (e.g., obesity, parity) and unmodified (race, age, etc.). Diagnosis of fibroids is simple – just an examination and ultrasound of the pelvis. Among the organ preservation methods of treatment are currently known medicinal (some of them can be used as mono-method or in combination with other methods), minimally invasive (among which stands out uterine artery embolization, as the most studied, effective and safe method) and surgical – conservative myomectomy, which can be performed by different approaches (laparoscopic, hysteroscopic or laparotomy) depending on the number and location of fibroids.
This review considers the issues of fertility in uterine fibroids and after organ preservation technologies for its treatment. Differential diagnosis of uterine fibroids with leiomyosarcoma – a rare tumor and its diagnosis is quite difficult.
The development of modern medical science, combining specialties with the formation of multidisciplinary teams (as in the case of collaboration with endovascular surgeons to perform uterine artery embolization) and use of an individual approach depending on the fibroids characteristics and patient needs helps reduce the proportion of hysterectomies for uterine fibroids, preservation of the organ and fertility.

Author Biographies

K.D. Plaksiieva, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

Graduate student, Endocrine Gynecology Department;
researcher, Department of Reproductive Health

T.F. Tatarchuk, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; State Scientific Institution “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv

MD, professor, corresponding member of the NAMS of Ukraine, deputy director for research work, head of the Endocrine Gynecology Department;
chief researcher, Department of Reproductive Health

N.V. Kosei, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine», Kyiv

MD, professor, chief researcher, Endocrine Gynecology Department;
head of Department of Reproductive Health,

K.Y. Melnyk, SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”, Kyiv

Postgraduate student, Endocrine Gynecology Department

O.S. Kozlov, О.О. Bogomolets National Medical University, Kyiv

Student

References

  1. Adusumilli, S., Hussain, H.K., Caoili, E.M., et al. “MRI of sonographically indeterminate adnexal masses.” Am J Roentgenol 187.3 (2006): 732–40. DOI: 10.2214/ajr.05.0905
  2. Akhter, S., Jahan, K., Afrose, R., et al. “Risk Association, Clinical Presentation and Management of Uterine Leiomyoma.” Mymensingh Med J 30.4 (2021): 907–12.
  3. Al-Hendy, A., Salama, S. “Gene therapy and Uterine Leiomyoma: A Review.” Hum Reprod Update 12.4 (2006): 385–400. DOI: 10.1093/humupd/dml015
  4. Ang, W.C., Farrell, E., Vollenhoven, B. “Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: A literature review.” Climacteric 4.4 (2001): 284–92. DOI: 10.1080/cmt.4.4.284.292
  5. Arthur, R., Kachura, J., Liu, G., et al. “Laparoscopic myomectomy versus uterine artery embolization: Long-term impact on markers of Ovarian Reserve.” J Obstet Gynaecol Canada 36.3 (2014): 240–7. DOI: 10.1016/s1701-2163(15)30632-0
  6. Bian, M.L., Huang, M.L., Zhang, Z.Y., et al. “Preoperative treatment of uterine fibroids with low-dose mifepristone: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study.” Zhonghua Fu Chan Ke Za Zhi 56.5 (2021): 317–27. DOI: 10.3760/cma.j.cn112141-20210411-00192
  7. Borah, B.J., Nicholson, W.K., Bradley, L., Stewart, E.A. “The impact of uterine leiomyomas: A national survey of affected women.” Am J Obstet Gynecol 209.4 (2013). DOI: 10.1016/j.ajog.2013.07.017
  8. Bradley, L.D., Falcone, T., Magen, A.B. “Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding.” Obstet Gynecol Clin North Am 27.2 (2000): 245–76. DOI: 10.1016/s0889-8545(00)80019-4
  9. Britten, J.L., Malik, M., Levy, G., et al. “Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.” Fertil Steril 98.5 (2012): 1299–1307. DOI: 10.1016/j.fertnstert.2012.07.1123
  10. Bulun, S.E. “Uterine fibroids.” N Engl J Med 369.14 (2013): 1344–55. DOI: 10.1056/nejmra1209993
  11. Cantuaria, G. “Comparison of bimanual examination with ultrasound examination before hysterectomy for uterine leiomyoma.” Obstet Gynecol 92.1 (1998): 109–12. DOI: 10.1016/s0029-7844(98)00131-8
  12. Chang, I.K.J., Hong, G.Y., Oh, Y.L., et al. “Effects of menopausal hormone therapy on uterine myoma in menopausal women.” J Menopausal Med 19.3 (2013): 123. DOI: 10.6118/jmm.2013.19.3.123
  13. Chen, Y., Xiong, N., Xiao, J., et al. “Association of uterine fibroids with increased blood pressure: a cross-sectional study and meta-analysis.” Hypertens Res 45.4 (2022): 715–21. DOI: 10.1038/s41440-022-00856-w
  14. da Silva, F., Pabalan, N., Ekaratcharoenchai, N., et al. “PROGINS Polymorphism of the Progesterone Receptor Gene and the Susceptibility to Uterine Leiomyomas: A Systematic Review and Meta-Analysis.” Genetic testing and molecular biomarkers 22.5 (2018): 295–301. DOI: 10.1089/gtmb.2017.0233
  15. Day Baird, D., Dunson, D.B., Hill, M.C., et al. “High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence.” Am J Obstet Gynecol 188.1 (2003): 100–7. DOI: 10.1067/mob.2003.99
  16. Deng, L., Wu, T., Chen, X.Y., et al. “Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.” Cochrane Database Syst Rev 10 (2012): CD005287. DOI: 10.1002/14651858.cd005287.pub4
  17. DeWaay, D.J., Syrop, C.H., Nygaard, I.E., et al. “Natural history of uterine polyps and Leiomyomata.” Obstet Gynecol 100.1 (2002): 3–7. DOI: 10.1097/00006250-200207000-00002
  18. Dicle, O., Küçükler, C., Pirnar, T., et al. “Magnetic resonance imaging evaluation of incision healing after cesarean sections.” Eur Radiol 7.1 (1997): 31–4. DOI: 10.1007/s003300050103
  19. Donnez, J., Tatarchuk, T.F., Bouchard, P., et al. “Ulipristal acetate versus placebo for fibroid treatment before surgery.” N Engl J Med 366.5 (2012): 409–20. DOI: 10.1056/nejmoa1103182
  20. Donnez, J., Tomaszewski, J., Vázquez, F., et al. “Ulipristal acetate versus leuprolide acetate for uterine fibroids.” N Engl J Med 366.5 (2012): 421–32. DOI: 10.1056/nejmoa1103180
  21. El Shamy, T., Amer, S.A., Mohamed, A.A., et al. “The impact of uterine artery embolization on Ovarian Reserve: A systematic review and meta-analysis.” Acta Obstetricia Et Gynecologica Scandinavica 99.1 (2019): 16–23. DOI: 10.1111/aogs.13698
  22. Elkafas, H., Badary, O., Elmorsy, E., et al. “Endocrine-Disrupting Chemicals and Vitamin D Deficiency in the Pathogenesis of Uterine Fibroids.” J Adv Pharm Res 5.2 (2021): 260–75. DOI: 10.21608/aprh.2021.66748.1124
  23. Emanuel, M.H., Wamsteker, K. “Fluid absorption during transcervical resection of submucous myomas related to the degree of intramural extension.” J Am Assoc Gynecol Laparosc 2.4 (1995). DOI: 10.1016/s1074-3804(05)80501-8
  24. Englund, K., Blanck, A., Gustavsson, I., et al. “Sex steroid receptors in human myometrium and fibroids: Changes during the menstrual cycle and gonadotropin-releasing hormone treatment.” J Clin Endocrinol Metab 83.11 (1998): 4092–6. DOI: 10.1210/jcem.83.11.5287
  25. Flake, G.P., Andersen, J., Dixon, D. “Etiology and pathogenesis of uterine leiomyomas: A review.” Environmental Health Perspectives 111.8 (2003): 1037–54. DOI: 10.1289/ehp.5787
  26. Friedman, A.J., Hoffman, D.I., Comite, F., et al. “Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study.” Int J Gynecol Obstet 38.2 (1992): 149. DOI: 10.1016/0020-7292(92)90069-u
  27. García, C.-R. “Management of the symptomatic fibroid in women older than 40 years of age.” Obstet Gynecol Clin North Am 20.2 (1993): 337–48. DOI: 10.1016/s0889-8545(21)00523-4
  28. Ghanaati, H., Sanaati, M., Shakiba, M., et al. “Pregnancy and its outcomes in patients after uterine fibroid embolization: A systematic review and meta-analysis.” Cardiovasc Intervent Radiol 43.8 (2020): 1122–33. DOI: 10.1007/s00270-020-02521-6
  29. Go, V., Thomas, M.C., Singh, B., et al. “A systematic review of the psychosocial impact of fibroids before and after treatment.” Am J Obstet Gynecol 223.5 (2020): 674–708.e8. DOI: 10.1016/j.ajog.2020.05.044
  30. Graif, A., Leung, D.A., McKenna, G., et al. “Evaluation of the effect of routine antibiotic administration after uterine artery embolization on infection rates.” J Vasc Intervent Radiol 31.8 (2020): 1263–9. DOI: 10.1016/j.jvir.2020.03.026
  31. Holdsworth-Carson, S.J., Zaitseva, M., Vollenhoven, B.J., Rogers, P.A.W. “Clonality of smooth muscle and fibroblast cell populations isolated from human fibroid and myometrial tissues.” MHR: Basic Science of Reproductive Medicine 20.3 (2013): 250–9. DOI: 10.1093/molehr/gat083
  32. Hoshiai, H., Seki, Y., Kusumoto, T., et al. “Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.” BMC Women’s Health 21.1 (2021): 375. DOI: 10.1186/s12905-021-01475-2
  33. Ip, P.P., Tse, K.Y., Tam, K.F. “Uterine smooth muscle tumors other than the ordinary leiomyomas and Leiomyosarcomas: A review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.” Adv Anat Pathol 17.2 (2010): 91–112. DOI: 10.1097/pap.0b013e3181cfb901
  34. Jin, C., Hu, Y., Chen, X.-C., et al. “Laparoscopic versus open myomectomy – a meta-analysis of randomized controlled trials.” Eur J Obstet Gynecol Reprod Biol 145.1 (2009): 14–21. DOI: 10.1016/j.ejogrb.2009.03.009
  35. Karlsen, K., Hrobjartsson, A., Korsholm, M., et al. “Fertility after uterine artery embolization of fibroids: A systematic review.” Arch Gynecol Obstet 297.1 (2017): 13–25. DOI: 10.1007/s00404-017-4566-7
  36. Ke, L.-Q., Yang, K., Li, J., Li, C.-M. “Danazol for uterine fibroids.” Cochrane Database Syst Rev 3 (2009): CD007692. DOI: 10.1002/14651858.cd007692
  37. Khaw, S.C., Anderson, R.A., Lui, M.-W. “Systematic review of pregnancy outcomes after fertility-preserving treatment of uterine fibroids.” Reprod BioMed Online 40.3 (2020): 429–44. DOI: 10.1016/j.rbmo.2020.01.003
  38. Kim, C.-W., Shim, H.S., Jang, H., Song, Y.G. “The effects of uterine artery embolization on Ovarian Reserve.” Eur J Obstet Gynecol Reprod Biol 206 (2016): 172–6. DOI: 10.1016/j.ejogrb.2016.09.001
  39. Kounidas, G., Kastora, S.L., Barnott, E., et al. “Efficacy of ulipristal acetate in women with fibroid induced menorrhagia: A systematic review and meta-analysis.” J Gynecol Obstet Hum Reprod 50.9 (2021): 102173. DOI: 10.1016/j.jogoh.2021.102173
  40. Kröncke, T., David, M. “Uterine artery embolization (UAE) for fibroid treatment – results of the 5th radiological gynecological expert meeting.” Geburtshilfe Und Frauenheilkunde 75.05 (2015): 439–41. DOI: 10.1055/s-0035-1545999
  41. Lasmar, R.B., Xinmei, Z., Indman, P.D., et al. “Feasibility of a new system of classification of Submucous Myomas: A multicenter study.” Fertil Steril 95.6 (2011): 2073–7. DOI: 10.1016/j.fertnstert.2011.01.147
  42. Leibsohn, S., d’Ablaing, G., Mishell, D.R., Schlaerth, J.B. “Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.” Am J Obstet Gynecol 162.4 (1990): 968–76. DOI: 10.1016/0002-9378(90)91298-q
  43. Lin, Y., Wu, R.C., Huang, Y.L., et al. “Uterine fibroid-like tumors: spectrum of MR imaging findings and their differential diagnosis.” Abdom Radiol (New York) 47.6 (2022): 2197–208. DOI: 10.1007/s00261-022-03431-6
  44. Lohle, P.N.M., Higué, D., Herbreteau, D. “Uterine artery embolisation in women with symptomatic uterine fibroids.” La Presse Médicale 48.4 (2019): 440–6. DOI: 10.1016/j.lpm.2019.03.012
  45. Machado-Lopez, A., Alonso, R., Lago, V., et al. “Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma.” Int J Mol Sci 23.4 (2022): 2190. DOI: 10.3390/ijms23042190
  46. Magalhães, J., Aldrighi, J.M., de Lima, G.R. “Uterine volume and menstrual patterns in users of the Levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.” Contraception 75.3 (2007): 193–8. DOI: 10.1016/j.contraception.2006.11.004
  47. Marshall, L. “Variation in the incidence of uterine leiomyoma among premenopausal women by age and race.” Obstet Gynecol 90.6 (1997): 967–73. DOI: 10.1016/s0029-7844(97)00534-6
  48. Maruo, T., Ohara, N., Yoshida, S., et al. “Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system.” Contraception 82.5 (2010): 435–41. DOI: 10.1016/j.contraception.2010.05.006
  49. McLucas, B., Voorhees, W.D., Snyder, S.A. “Anti-müllerian hormone levels before and after uterine artery embolization.” Minim Invasive Ther Allied Technol 27.3 (2017): 186–90. DOI: 10.1080/13645706.2017.1365728
  50. Mlodawska, O.W., Saini, P., Parker, J.B., et al. “Epigenomic and enhancer dysregulation in uterine leiomyomas.” Hum Reprod Update (2022): dmac008. DOI: 10.1093/humupd/dmac008
  51. Moro, E., Degli Esposti, E., Borghese, G., et al. “The impact of hormonal replacement treatment in postmenopausal women with uterine fibroids: A state-of-the-art review of the literature.” Medicina 55.9 (2019): 549. DOI: 10.3390/medicina55090549
  52. Muhammad, J., Yusof, Y., Ahmad, I., Norhayati, M.N. “Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.” BMC Women’s Health 22.1 (2022): 14. DOI: 10.1186/s12905-022-01596-2
  53. Munro, M.G., Critchley, H.O.D., Broder, M.S., Fraser, I.S. “FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age.” Int J Gynecol Obstet 113.1 (2011): 3–13. DOI: 10.1016/j.ijgo.2010.11.011
  54. Myers, E. “Management of uterine leiomyomata: What do we really know?” Obstet Gynecol 100.1 (2002): 8–17. DOI: 10.1016/s0029-7844(02)02019-7
  55. Panidis, D., Vavilis, D., Rousso, D., et al. “Danazol influences gonadotropin secretion acting at the hypothalamic level.” Int J Gynecol Obstet 45.3 (1994): 241–6. DOI: 10.1016/0020-7292(94)90249-6
  56. Parker, W.H., Fu, Y.S., Berek, J.S. “Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.” Obstet Gynecol 83.4 (1994): 14–8.
  57. Peddada, S.D., Laughlin, S.K., Miner, K., et al. “Growth of uterine leiomyomata among premenopausal black and white women.” Proceedings of the National Academy of Sciences 105.50 (2008): 19887–92. DOI: 10.1073/pnas.0808188105
  58. Pérez-Roncero, G.R., López-Baena, M.T., Ornat, L., et al. “Uterine fibroids and preterm birth risk: A systematic review and meta-analysis.” J Obstet Gynaecol Res 46.9 (2020): 1711–27. DOI: 10.1111/jog.14343
  59. Qin, H., Lin, Z., Vásquez, E., et al. “Association between obesity and the risk of uterine fibroids: a systematic review and meta-analysis.” J Epidemiol Community Health 75.2 (2021): 197–204. DOI: 10.1136/jech-2019-213364
  60. Reissmann, T., Diedrich, K., Comaru-Schally, A.M., Schally, A.V. “Introduction of LHRH-antagonists into the treatment of Gynaecological Disorders.” Hum Reprod 9.5 (1994): 767–9. DOI: 10.1093/oxfordjournals.humrep.a138593
  61. Russ, M., Hees, K.A., Kemmer, M., et al. “Preoperative Uterine Artery Embolization in Women Undergoing Uterus-Preserving Myomectomy for Extensive Fibroid Disease: A Retrospective Analysis.” Gynecol Obstet Invest 1.87 (2022): 38–45. DOI: 10.1159/000521914
  62. Sayed, G.H., Zakherah, M.S., El-Nashar, S.A., Shaaban, M.M. “A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia.” Int J Gynecol Obstet 112.2 (2010): 126–30. DOI: 10.1016/j.ijgo.2010.08.009
  63. Sinha, R., Hegde, A., Warty, N., Patil, N. “Laparoscopic excision of very large myomas.” J Am Assoc Gynecol Laparosc 10.4 (2003): 461–8. DOI: 10.1016/s1074-3804(05)60145-4
  64. Song, H., Lu, D.H., Navaratnam, K., Shi, G. “Aromatase inhibitors for uterine fibroids.” Cochrane Database Syst Rev 10 (2013): CD009505. DOI: 10.1002/14651858.cd009505.pub2
  65. Spyropoulou, K., Kosmas, I., Tsakiridis, I., et al. “Myomectomy during pregnancy: A systematic review.” Eur J Obstet Gynecol Reprod Biol 254 (2020): 15–24. DOI: 10.1016/j.ejogrb.2020.08.018
  66. Sumitani, H., Shozu, M., Segawa, T., et al. “In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism”. Endocrinology 141.10 (2000): 3852–61. DOI: 10.1210/endo.141.10.7719
  67. Suzuki, A., Aoki, M., Miyagawa, C., et al. “Differential diagnosis of uterine leiomyoma and uterine sarcoma using magnetic resonance images: A literature review.” Healthcare 7.4 (2019): 158. DOI: 10.3390/healthcare7040158
  68. Tatarchuk, T.F., Kosey, N.V., Regeda, S.I., et al. “To the question on uterine fibroids during pregnancy.” Scientific Digest of Association of Obstetricians and Gynecologists of Ukraine 1.47 (2021): 54–9. DOI: 10.35278/2664-0767.1(47).2021.242698
  69. Templeman, C., Marshall, S.F., Clarke, C.A., et al. “Risk factors for surgically removed fibroids in a large cohort of teachers.” Fertil Steril 92.4 (2009): 1436–46. DOI: 10.1016/j.fertnstert.2008.08.074
  70. Travaglino, A., Raffone, A., Gencarelli, A., et al. “p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP).” Pathol Res Pract 226 (2021): 153592. DOI: 10.1016/j.prp.2021.153592
  71. Tsai, M.C., Chang, L.T., Tam, K.W. “Comparison of High-Intensity Focused Ultrasound and Conventional Surgery for Patients with Uterine Myomas: A Systematic Review and Meta-Analysis.” J Minim Invasive Gynecol 28.10 (2021): 1712–24. DOI: 10.1016/j.jmig.2021.06.002
  72. Tsikouras, P., Manav, B., Koukouli, Z., et al. “Ovarian Reserve after fibroid embolization in premenopausal women.” Minim Invasive Ther Allied Technol 26.5 (2017): 284–91. DOI: 10.1080/13645706.2017.1292919
  73. Vahdat, M., Allahqoli, L., Mirzaei, H., et al. “The effect of vitamin D on recurrence of uterine fibroids: A randomized, double-blind, placebo-controlled pilot study.” Complement Ther Clin Pract 46 (2022): 101536. DOI: 10.1016/j.ctcp.2022.101536
  74. Vercellini, P., Giorgio Crosignani, P., Mangioni, C., et al. “Treatment with a gonadotrophin releasing hormone agonist before hysterectomy for leiomyomas: Results of a multicentre, randomised controlled trial.” BJOG 105.11 (1998): 1148–54. DOI: 10.1111/j.1471-0528.1998.tb09967.x
  75. Vilos, G.A., Marks, J., Ettler, H.C., et al. “Uterine smooth muscle tumors of uncertain malignant potential: Diagnostic challenges and therapeutic dilemmas. Report of 2 cases and review of the literature.” J Minim Invasive Gynecol 19.3 (2012): 288–95. DOI: 10.1016/j.jmig.2011.12.025
  76. Vilos, G.A., Ternamian, A., Dempster, J., et al. “Laparoscopic entry: A review of techniques, technologies, and complications.” J Obstet Gynaecol Canada 29.5 (2007): 433–47. DOI: 10.1016/s1701-2163(16)35496-2
  77. Vitagliano, A., Noventa, M., Di Spiezio Sardo, A., et al. “Uterine fibroid size modifications during pregnancy and puerperium: Evidence from the first systematic review of literature.” Arch Gynecol Obstet 297.4 (2017): 823–35. DOI: 10.1007/s00404-017-4621-4
  78. Wise, L.A., Thomas, L., Anderson, S., et al. “Route of myomectomy and fertility: A prospective cohort study.” Fertil Steril 117.5 (2022): 1083–93. DOI: 10.1016/j.fertnstert.2022.01.013
  79. Xu, F., Deng, L., Zhang, L., et al. “The comparison of myomectomy, UAE and MRgFUS in the treatment of uterine fibroids: a metaanalysis.” Int J Hyperthermia 38.2 (2021): 24–9. DOI: 10.1080/02656736.2021.1933216
  80. Yan, L., Huang, H., Lin, J., Yu, R. “High-intensity focused ultrasound treatment for symptomatic uterine fibroids: a systematic review and meta-analysis.” Int J Hyperthermia 39.1 (2022): 230–8. DOI: 10.1080/02656736.2022.2029956
  81. Zhang, J., Go, V.A., Blanck, J.F., Singh, B. “A Systematic Review of Minimally Invasive Treatments for Uterine Fibroid-Related Bleeding.” Reprod Sci (2021). DOI: 10.1007/s43032-021-00722-z

Downloads

Published

2022-05-27

How to Cite

Plaksiieva, K., Tatarchuk, T., Kosei, N., Melnyk, K., & Kozlov, O. (2022). Uterine fibroids: synthesis of modern knowledge: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (63-64), 8–18. https://doi.org/10.18370/2309-4117.2022.63.8-18

Issue

No. 63-64 (2022)

Section

Tumors and pretumoral pathology

License

Copyright (c) 2022 К.Д. Плаксієва, Т.Ф. Татарчук, Н.В. Косей, К.Є. Мельник, О.С. Козлов

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.